
Beam Therapeutics Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing, a technology that makes single-letter changes to DNA to correct disease-causing mutations without cutting the DNA strand. Its pipeline targets diseases including sickle cell disease, alpha-1 antitrypsin deficiency, and other genetic and immune-related conditions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Evans John M.CEO | Sell | $600K | 25,000at $23.98 | Oct 16, 2026 |
| Evans John M.CEO | Sell | $589K | 25,000at $23.57 | Oct 15, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BEAM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.